Partnership for health equity

Health is a fundamental human right. Everyone should have a fair opportunity to attain their highest level of health, regardless of social, economic, geographic, or demographic circumstances. This vision is at the core of universal healthcare (UHC), and it is why the research-based pharmaceutical industry remains committed to leveraging innovation to advance health equity.

- 

Three foundational elements anchor this commitment: strengthening primary healthcare, ensuring sustainable financing, and promoting multi-stakeholder partnerships. In the Philippines, the PHAPCares Foundation, the social responsibility arm of the Pharmaceutical and Healthcare Association of the Philippines (PHAP), works closely with member companies to turn these priorities into action. One shining example is its collaboration with Boehringer Ingelheim, whose programs have become models of how industry can help reduce inequities and improve access to care.

“Partnerships are the cornerstone of sustainable impact. Our collaboration with the PHAPCares Foundation exemplifies how collective action can drive meaningful change in public health and social development. Through this alliance, we’ve been able to align our corporate social responsibility goals with broader national priorities — extending our reach, deepening our engagement, and ensuring that our initiatives are both responsive and relevant,” said Dr. Bin Wang, General Manager of Boehringer Ingelheim Philippines.

For Boehringer Ingelheim, corporate social responsibility is not peripheral; it is a direct expression of their purpose: Transforming Lives for Generations. Guided by its Sustainable Development for Generations (SD4G) framework, the company aligns its initiatives with the United Nations Sustainable Development Goals. Of its three pillars, “More Health” stands out for expanding access to healthcare and preventive solutions, particularly in underserved communities.